Skip to main content

Advertisement

Fig. 2 | Molecular Cancer

Fig. 2

From: GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

Fig. 2

GLIPR1-ΔTM increased the apoptotic effect of docetaxel in VCaP and PC-3 cells. a. The addition of 10 μg/ml GLIPR1-ΔΤΜ increased the apoptotic effects of all docetaxel’s doses in VCaP cells, measured by DAPI staining. b. The addition of 10 μg/ml GLIPR1-ΔΤΜ increased the apoptotic effects of all docetaxel doses in PC-3 cells, measured by DAPI staining. c. GLIPR1-ΔΤΜ did not increase the apoptotic effect of any docetaxel dose in RWPE-1 cells, while 1nM docetaxel significantly increased the percentage of apoptotic cells, based on DAPI staining. d. The addition of 10 μg/ml GLIPR1-ΔΤΜ increased the apoptotic effects of all docetaxel doses in VCaP cells, measured by DNA fragmentation. e. The addition of 10 μg/ml GLIPR1-ΔΤΜ increased the apoptotic effects of all docetaxel doses in PC-3 cells, measured by DNA fragmentation. f. GLIPR1-ΔΤΜ did not increase the apoptotic effect of any docetaxel dose in RWPE-1 cells, while 0.5nM docetaxel significantly increased the percentage of apoptotic cells, based on DNA fragmentation. The results are presented as the mean ± standard error from at least three independent experiments

Back to article page